- Language: English
- 208 Pages
- Published: October 2013
- Region: Europe
Global Orphan Drugs Market 2014-2018
- ID: 2757627
- January 2014
- Region: Global
- 66 pages
The analysts forecast the Global Orphan Drugs market to grow at a CAGR of 5.67 percent over the period 2013-2018. One of the key factors contributing to this market growth is the shorter development timelines. The Global Orphan Drugs market has also been witnessing the growing awareness of orphan drugs. However, the high cost of drug development could pose a challenge to the growth of this market.
The report, the Global Orphan Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it also covers the Global Orphan Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key vendors dominating this space are Novartis AG, F. Hoffmann-La Roche Ltd., Celgene Corp., Pfizer Inc., and Sanofi S.A.
Other vendors mentioned in the report are Actelion Pharmaceuticals Ltd., Alexion Pharmaceuticals Inc., Amgen Inc., Baxter International Inc., Biogen Idec Inc., Bristol-Myers-Squibb Co., GlaxoSmithKline plc, Eli Lilly & Co., Merck KGaA, Novo Nordisk A/S, Onyx Pharmaceuticals Inc., Shire plc, and Vertex Pharmaceuticals Inc.
Key questions answered in this report:
- What will the market size be in 2018 and what will the growth rate be?
- What are the key market trends?
- What is driving this market?
- What are the challenges to market growth?
- Who are the key vendors in this market space?
- What are the market opportunities and threats faced by the key vendors?
- What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report. SHOW LESS READ MORE >
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Global Biologics Orphan Drugs Market
Market Size and Forecast
06.4 Global Non-Biologic Orphan Drugs Market
Market Size and Forecast
06.5 Five Forces Analysis
07. Market Segmentation by Product
08. Geographical Segmentation
09. Buying Criteria
10. Market Growth Drivers
11. Drivers and their Impact
12. Market Challenges
13. Impact of Drivers and Challenges
14. Market Trends
15. Trends and their Impact
16. Vendor Landscape
16.1 Competitive Scenario
16.1.1 Key News
16.1.2 Mergers and Acquisitions
16.2 Market Share Analysis 2012
16.3 Other Prominent Vendors
17. Key Vendor Analysis
17.1 Novartis AG
17.1.1 Business Overview
17.1.2 Business Segmentation
17.1.3 Key Information
17.1.4 SWOT Analysis
17.2 F. Hoffmann La Roche Ltd.
17.2.1 Business Overview
17.2.2 Business Segmentation
17.2.3 Key Information
17.2.4 SWOT Analysis
17.3 Celgene Corp.
17.3.1 Business Overview
17.3.2 Key Information
17.3.3 SWOT Analysis
17.4 Pfizer Inc.
17.4.1 Business Overview
17.4.2 Key Information
17.4.3 SWOT Analysis
17.5 Sanofi S.A.
17.5.1 Business Overview
17.5.2 Business Segmentation
17.5.3 Key Information
17.5.4 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Orphan Drugs Market 2013-2018 (US$ billion)
Exhibit 3: Global Biologics Orphan Drugs Market 2013-2018 (US$ billion)
Exhibit 4: Global Non-Biologic Orphan Drugs Market 2013-2018 (US$ billion)
Exhibit 5: Global Orphan Drugs Market Segmentation 2013-2018 (by percentage)
Exhibit 6: Global Orphan Drugs Market Segmentation by Product
Exhibit 7: Global Orphan Drugs Market Segmentation 2013
Exhibit 8: Global Orphan Drugs Market by Geographical Segmentation 2013
Exhibit 9: FDA Approval Time: Orphan vs. Non-Orphan (months)
Exhibit 10: Phase Three Trial Length (yrs) Orphan vs. Non-Orphan
Exhibit 11: Global Orphan Drugs Market by Vendor Segmentation 2013
Exhibit 12: Global Orphan Drugs Market by Vendor Segmentation 2018
Exhibit 13: Global Orphan Drug Sales: Top 20 companies 2013-2018
Exhibit 14: Global USA and EU Orphan Designations per year (2009-2012)
Exhibit 15: Business Segmentation of Novartis AG
Exhibit 16: Business Segmentation of F. Hoffmann La Roche Ltd.
Exhibit 17: Business Segmentation of Sanofi S.A.
Commenting on the report, an analyst from the team said: “There has been increase in awareness about the potential benefits of orphan drugs among patients, surgeons, and hospitals. Public awareness about the use of orphan drugs is rapidly growing as a result of increasing social and public exposure and more advocacy groups and awareness campaigns. For instance, in 2010, the US FDA created the Rare Disease Program within the Office of New Drugs with the specific focus of developing the policies and procedures for the review of new drug applications for orphan drug products and to ensure access to appropriate training for US FDA reviewers. Similarly in 2012, the US FDA hosted the first ever US FDA Rare Disease Patient Advocacy Day to enhance the rare disease patient advocacy community’s awareness of the US FDA’s roles and responsibilities in the development of products for rare diseases. Thus, with the increasing awareness of orphan drugs, the market is expected to witness positive growth in the near future.”
According to the report, one of the main drivers in this market is the shorter development timelines. The clinical trials of orphan drugs for rare diseases involve fewer patients, which contributes to a shorter development process.
Further, the report states that one of the main challenges is the high cost of drug development. The rise in the cost of drug development often tends to discourage pharmaceutical innovators from developing orphan drugs.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry.
The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
- Novartis AG
- F. Hoffmann-La Roche Ltd.
- Celgene Corp.
- Pfizer Inc.
- and Sanofi S.A.